Tetra Bio-Pharma Inc. - TBPMF STOCK NEWS

Tetra Bio-Pharma announced Health Canada approved an amendment to a phase I study assessing the effects of inhaled CBD on healthy cannabinoid users. In collaboration with the University of Montreal Hospital Research Centre (CRCHUM), Tetra aims to gather critical clinical data on the safety and biological effects of CBD at dosages up to 100 mg. The study will involve 80 healthy adults aged 21-65 and is funded by Quebec's health department. This collaboration enhances Tetra's research efforts in cannabinoid science, advancing understanding of CBD's impact on human health.

Tetra Bio-Pharma has entered a licensing agreement with Thorne Health Tech for the commercialization of a patented prebiotic dietary supplement in the U.S. market. This partnership includes royalties on sales and milestone payments. The U.S. prebiotics market is projected to surpass USD 9.5 billion by 2027, growing at a CAGR of 9.6% from 2021. Tetra's CEO expressed enthusiasm about collaborating with Thorne, known for its evidence-based supplements, to bring their product to consumers.

Tetra Bio-Pharma has secured a $4.5M CDN participative loan from the ministère de l'Économie et de l'Innovation to advance its drug ARDS-003, targeting acute respiratory distress syndrome and Sepsis. This funding is conditional upon shareholder approval, with a vote scheduled for May 2022. With a significant portion of its workforce in Quebec, Tetra aims to relocate its head office from Ontario. The government views this support as vital for bolstering Quebec's life sciences sector, enhancing Tetra's growth potential in cannabinoid-derived therapies.

Tetra Bio-Pharma has signed a non-binding term sheet with Avicanna to explore a strategic partnership with three pillars: commercialization of prescription products in South America, supply of Avicanna's Active Pharmaceutical Ingredients (APIs), and co-development of pharmaceutical drug candidates. This collaboration could accelerate Tetra's sales efforts and leverage Avicanna’s distribution capabilities for its products like QIXLEEF™. The partnership aims to enhance both companies' foothold in the cannabinoid pharmaceutical market, supporting their growth and innovation strategies.

Tetra Bio-Pharma announced a Type C meeting with the FDA to discuss marketing authorization requirements for its investigational inhaled drug, QIXLEEF™. This drug, which combines THC and CBD, meets the FDA’s standards for inhalation aerosols. The company received positive feedback from the Malta Medicines Authority earlier this year, confirming the adequacy of its nonclinical safety strategy. CEO Guy Chamberland emphasized the importance of FDA guidance to ensure cost-effective market entry for QIXLEEF™. Tetra Bio-Pharma focuses on cannabinoid-derived drug development for various medical conditions.

OTTAWA, ON, Nov. 29, 2021 /PRNewswire/ - Tetra Bio-Pharma announced initial positive clinical data from its Phase 2 trials (REBORN and PLENITUDE) of QIXLEEF™ for cancer pain. QIXLEEF™, a botanical inhaled formulation of THC and CBD, meets USA cGMP standards. The REBORN trial compares QIXLEEF™ to oral opioids for breakthrough pain management, while PLENITUDE assesses its efficacy in uncontrolled cancer pain. Safety data confirmed a good profile with no serious adverse events reported. CEO Guy Chamberland emphasized the need for non-opioid pain management alternatives, highlighting QIXLEEF™'s rapid onset and tolerability.

Tetra Bio-Pharma announced the termination of its at-the-market equity offering program, effective November 11, 2021. The program, initiated on May 28, 2021, allowed for up to $10 million in common shares to be sold, but no shares were issued under this program. Tetra Bio-Pharma focuses on cannabinoid-derived drug discovery and development, with cleared clinical programs aimed at producing novel prescription drugs for various medical conditions.

Tetra Bio-Pharma announced a positive opinion from the European Medicines Agency (EMA) for its investigational drug QIXLEEF™ as a treatment for Complex Regional Pain Syndrome (CRPS). This opinion from the Committee for Orphan Medicinal Products (COMP) supports Tetra's application for Orphan Drug Designation (ODD), which can lead to a faster review process, reduced drug development costs, and market exclusivity for 10 years. This would be QIXLEEF's second ODD, following the FDA designation in March 2018. The company aims to provide a safer, non-opioid pain management solution.

Tetra Bio-Pharma provided an update on its lead investigational drug, QIXLEEF™, a cannabinoid-based inhaled medication designed for cancer patients suffering from uncontrolled breakthrough pain. The drug is undergoing rigorous clinical trials, having successfully completed Phase 1 trials that confirmed its safety and efficacy in delivering cannabinoids effectively. Tetra aims to initiate the final stage of drug development and is currently in discussions for global supply partnerships. Positive feedback from European regulatory authorities supports the marketing approval path.